SSY Group (1530.HK) fell 4.03% in Hong Kong trading to HK$13.35, touching a 52-week low.
The decline came after the US Treasury released a draft "Comprehensive Outbound Investment National Security Act" proposing restrictions on investment in China's biotech sector. Investors fear the policy could hamper equity financing and cross-border licensing partnerships for Chinese innovative drugmakers, dragging down the broader sector.
At the company level, SSY Group has been actively repurchasing shares, buying back 337,500 shares for HK$4.86 million on Oct. 14 and 800,000 shares for HK$11.65 million on Oct. 13. DBS initiated coverage in mid-October with a buy rating and a target price of HK$17.8, citing the company's pipeline and licensing growth potential. SSY Group previously secured a $1.25 billion upfront payment from Pfizer for a bispecific antibody licensing deal and reached an exclusive commercialization agreement with MindRank on MDR-001, an AI-designed oral GLP-1 weight-loss drug, with a potential total deal value of up to 1.75 billion yuan.
